Ocular Drug Delivery Global Market By Formulation Type, By Technology, By Material, By Disease Indication, By End User, By Regional Forecasts, 2024-2033 | Pfizer Inc., Roche Holding AG, AbbVie Inc., Novartis AG, Allergan Inc.

Spread the love

Overview and Scope
Ocular drug delivery refers to the administration of medications or therapeutic agents to the eye. It involves delivering drugs to various ocular tissues, such as the cornea, conjunctiva, retina, or intraocular structures, to treat various eye conditions.

Sizing and Forecast
The ocular drug delivery market size has grown strongly in recent years. It will grow from $17.39 billion in 2023 to $18.64 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rise in ocular diseases, aging population trends, advancements in pharmaceutical formulations, clinical advancements in ophthalmology, prevalence of diabetes-related eye conditions.

The ocular drug delivery market size is expected to see strong growth in the next few years. It will grow to $24.98 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to rising incidence of age-related eye diseases, focus on personalized medicine in ophthalmology, increased investment in ophthalmic research, demand for prolonged drug release, global initiatives for eye health. Major trends in the forecast period include integration of smart drug delivery devices, personalized medicine in ocular drug formulations, development of topical ophthalmic therapies, collaborations for cross-industry innovations..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/ocular-drug-delivery-global-market-report

Segmentation & Regional Insights
The ocular drug delivery market covered in this report is segmented –
1) By Technology: Implantable Ocular Drug Delivery Systems, Particulate Drug Delivery Systems, Nano-Particle Drug Delivery System, Other Technologies
2) By Formulation: Liposomes And Nanoparticles, Solution, Emulsion, Suspension, Ointment
3) By Disease: Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Macular Degeneration, Cataract, Diabetic Macular Edema, Other Diseases
4) By End User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

North America was the largest region in the ocular drug delivery market in 2023. The regions covered in the ocular drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11901&type=smp

Major Driver Impacting Market Growth
An increase in the prevalence of eye disorders is expected to propel the growth of the ocular drug delivery market going forward. Eye disorders refer to a wide range of conditions that affect the eyes, vision, or the structures surrounding the eyes. Ocular drug delivery allocates medications directly to the target site, providing greater drug concentrations at the targeted area, optimizing therapeutic efficacy while avoiding systemic adverse effects, and improving eye disorders. For instance, in March 2023, according to the World Health Organization, a Switzerland-based United Nations agency, globally, 2.2 billion people will have a near- or far-sighted impairment. According to estimates, cataracts (94 million) and uncorrected refractive problems (88.4 million) are the main causes of visual loss or impaired vision. In addition, glaucoma (7.7 million cases), corneal opacities (4.2 million cases), diabetic retinopathy (3.9 million cases), and trachoma (2 million cases) are the other common causes of vision loss. Therefore, the increase in the prevalence of eye disorders is driving the growth of the ocular drug delivery market.

Key Industry Players
Major companies operating in the ocular drug delivery market report are Pfizer Inc., Roche Holding AG, AbbVie Inc., Novartis AG, Allergan Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Santen Pharmaceutical Co. Ltd., Akorn Inc., Valeant Pharmaceuticals International Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Ophthotech Corporation, Acucela Inc., Graybug Vision Inc., Amakem NV, Kala Pharmaceuticals Inc., Icon Bioscience Inc., Clearside Biomedical Inc., Aerpio Therapeutics Inc., Senju Pharmaceutical Co. Ltd., Shire plc, Spark Therapeutics Inc., Sucampo Pharmaceuticals Inc., Carl Zeiss Meditec AG, EyeGate Pharmaceuticals Inc.

The ocular drug delivery market report table of contents includes:
1. Executive Summary